EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baseline Biomarkers for Three-Year Fibrosis Development on OCT in Treatment-Naïve Neovascular AMD

Malcolm Fayers, Long T. Phan, Eden McDonogh, Kimberly L. Spooner, Andrew A. Chang, Hemal Mehta, James G. Wong

Journal of Personalized Medicine · 30.10.2026 · 16 (11) · 560

DOI: 10.3390/jpm16110560 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 30.10.2026. Verfasst von Malcolm Fayers und 6 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To explore how baseline biomarkers on optical coherence tomography (OCT) predict fibrotic development in eyes with neovascular age-related macular degeneration (nAMD) commencing intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy.

Methods

Medical records at a single institution were retrospectively searched to identify eyes starting anti-vascular endothelial growth factor therapy with 36-month follow-up. Baseline OCT images were graded for central subfield thickness (CST) and nAMD lesion features. The development of fibrosis was determined after three years using an OCT-based approach, and multivariable logistic regression was used to identify independent predictors.

Results

A total of 201 eyes were included, of mean age 77.3 years. At baseline, median visual acuity (VA) was 67 (IQR 58–77) letters, and mean central subfield thickness (CST) was 398.6 ± 135.3 µm. Mean injections received were 9.8 ± 1.9, 8.1 ± 3.1, and 7.3 ± 3.2 in years 1, 2, and 3, respectively. Fibrosis developed in 53 eyes (26.4%) by three years. Lower baseline VA (OR 0.68 per 10 letters, p = 0.006), as well as presence of subretinal hyperreflective material (SHRM; OR 10.80, p < 0.001), intraretinal fluid (IRF; OR 2.60, p = 0.025), and type 2 macular neovascularisation (MNV; OR 2.98, p = 0.033) were each independently associated with fibrosis, while drusen presence was protective (OR 0.25, p = 0.002). Fibrosis occurred in 4.6% of eyes without SHRM and 43.0% with SHRM. In exploratory unadjusted analyses, odds of fibrosis were higher with SHRM height 1–99 µm (OR 6.2, 95% CI 1.8–21.7) and ≥100 µm (OR 23.7, 95% CI 7.9–71.3) than with no SHRM, and higher with ≥100 µm than 1–99 µm (OR 3.8, 95% CI 1.6–9.1; p = 0.003).

Conclusions

Subretinal hyperreflective material was the strongest baseline biomarker for developing subretinal fibrosis following anti-VEGF therapy in this historical cohort, with exploratory analyses suggesting higher risk at SHRM ≥ 100 µm. In combination with other biomarkers, these features may support future risk stratification in treatment-naïve neovascular age-related macular degeneration.

Zitieren

APA

Fayers, M., Phan, L. T., McDonogh, E., Spooner, K. L., Chang, A. A., Mehta, H., & Wong, J. G. (2026). Baseline Biomarkers for Three-Year Fibrosis Development on OCT in Treatment-Naïve Neovascular AMD. Journal of Personalized Medicine, 16(11), 560. https://doi.org/10.3390/jpm16110560

Vancouver

Fayers M, Phan LT, McDonogh E, Spooner KL, Chang AA, Mehta H, et al. Baseline Biomarkers for Three-Year Fibrosis Development on OCT in Treatment-Naïve Neovascular AMD. Journal of Personalized Medicine. 2026;16(11):560. doi:10.3390/jpm16110560

BibTeX
@article{Fayers2026,
  author = {Fayers, Malcolm and Phan, Long T. and McDonogh, Eden and Spooner, Kimberly L. and Chang, Andrew A. and Mehta, Hemal and Wong, James G.},
  title = {Baseline Biomarkers for Three-Year Fibrosis Development on OCT in Treatment-Naïve Neovascular AMD},
  journal = {Journal of Personalized Medicine},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {560},
  doi = {10.3390/jpm16110560}
}
Kostenlos starten →